• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Hypoxia-inducible factor-1: a promising therapeutic target for autoimmune diseases
【24h】

Hypoxia-inducible factor-1: a promising therapeutic target for autoimmune diseases

机译：缺氧诱导因子-1：自身免疫疾病的有希望的治疗靶标

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Hypoxia-inducible factor-1 (HIF-1) plays a crucial role in both innate and adaptive immunity. Emerging evidence indicates that HIF-1 is associated with the inflammation and pathologic activities of autoimmune diseases.Areas covered: Considering that the types of autoimmune diseases are complicated and various, this review aims to cover the typical kinds of autoimmune diseases, discuss the molecular mechanisms, biological functions and expression of HIF-1 in these diseases, and further explore its therapeutic potential.Expert opinion: Inflammation and hypoxia are interdependent. HIF-1 as a key regulator of hypoxia, exerts a crucial role in the balance between Th17 and Treg, and involves in the inflammation and pathologic activities of autoimmune diseases. Although there are many challenges remaining to be overcome, targeting HIF-1 could be a promising strategy for autoimmune diseases therapies.
机译：介绍：缺氧 - 诱导因子-1（HIF-1）在先天和适应性免疫中起着至关重要的作用。 新兴的证据表明，HIF-1与自身免疫疾病的炎症和病理活性有关。覆盖：考虑到自身免疫疾病的类型是复杂的，旨在涵盖典型的自身免疫疾病，讨论分子机制 这些疾病中HIF-1的生物学功能和表达，进一步探索其治疗潜力。症意见：炎症和缺氧是相互依存的。 HIF-1作为缺氧的关键调节剂，对TH17和Treg之间的平衡发挥至关重要的作用，涉及自身免疫疾病的炎症和病理活动。 虽然仍有许多挑战待克服，但靶向HIF-1可能是自身免疫疾病治疗的有希望的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号